Cellens

Cellens is pioneering a new modality in cancer diagnostics—an AI-driven mechanobiology platform, BioFeel™—to bring clarity and comfort to cancer monitoring. The technology platform creates a fundamentally new class of biomarkers to detect recurrence early, accurately and without invasive procedures. Cellens’s mission is to improve patients' quality of care by giving physicians the actionable information they need to make timely and confident decisions. Starting with bladder cancer, the company is building a future where cancer monitoring is simple, precise, and patient-friendly.